COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in ItalyResearch article Published on 2021-11-012022-10-05 Journal: European journal of cancer (Oxford, England : 1990 [Category] SARS, 치료법, [키워드] administration antibodies antibody anticancer anticancer treatment baseline BNT162b2 Cancer cancer patient Cancer patients cancer progression composed conducted consecutive patient control group coronavirus disease COVID-19 COVID-19 antibody COVID-19 infection COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine evaluate evaluated Factor GRADE healthy volunteers high risk IgG IgG titer immunogenic Italy Male sex median median age metastatic disease Patient prospective observational study receive reported Result RNA-1273 safety profile SARS-CoV-2 second dose secondary Seroconversion Seropositivity serum sample Side-effects significantly lower solid cancer solid tumour the vaccine therapy Treatment tumour two-dose regimen vaccination Vaccine vaccine dose were excluded [DOI] 10.1016/j.ejca.2021.08.035 [Article Type] Research article
Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 20202020년 여름 오스트리아 티롤 주의 건강한 헌혈자에서 SARS-CoV-2 항체의 유행Observational Study Published on 2021-10-262022-09-12 Journal: Wiener Klinische Wochenschrift [Category] MERS, SARS, 임상, 진단, [키워드] 95% CI 95% confidence interval Abbott acute respiratory syndrome acute respiratory syndrome coronavirus age antibody association Blood blood donor Blood donors Characteristics Cohort COVID-19 cross-sectional Cross-sectional studies determine District Donor Epidemiology female finding fold Gender health authorities Health authority healthy blood donor healthy blood donors IgG immunoassay individual Landeck Local Logistic regression Loss of Smell medication Microparticle not differ Observational cohort study Odds ratio participant reported SARS-CoV-2 antibody SARS-CoV‑2 SARS-CoV‑2 infection screened seronegative seropositive participant seropositive participants Seropositivity Seroprevalence severe acute respiratory syndrome Coronavirus Spread summer Symptoms Taste tested Travel Variation [DOI] 10.1007/s00508-021-01963-3 PMC 바로가기 [Article Type] Observational Study
Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India인도 델리에서 신흥 SARS-COV-2 변형의 게놈 특성 및 역학Article Published on 2021-10-222022-09-10 Journal: Science (New York, N.y.) [Category] Fulltext, MERS, 변종, 유전자 메커니즘, [키워드] (Alpha) antibody B.1.1.7 Bayesian city Cohort Combination Concentration contributed COVID-19 case COVID-19 cases Delta delta variant explain growth advantage immune response immune responses Immunity India median National outbreak reached reduced reduction replaced SARS-CoV-2 SARS-CoV-2 variant sensitivity Seropositivity Transmissibility variant variant B.1.617.2 [DOI] 10.1126/science.abj9932 PMC 바로가기 [Article Type] Article
High SARS-CoV-2 seroprevalence in persons experiencing homelessness and shelter workers from a day-shelter in São Paulo, Brazil브라질 상파울루의 주간 보호소에서 노숙자 및 보호소 직원을 경험한 사람의 높은 SARS-CoV-2 혈청 유병률Research Article Published on 2021-10-192022-09-12 Journal: PLoS Neglected Tropical Diseases [Category] MERS, SARS, 진단, [키워드] a homeless population addressed anti-SARS-CoV-2 IgM black Brazil carried city collected coronavirus COVID-19 death ELISA groups higher risk highest Homeless population IgG antibodies IgG antibody IgM and IgG indicate individuals initial molecular nasopharyngeal National no statistical difference No statistical differences oropharyngeal swab pandemic Population populations Prevalence protective factor rising risk risk factor RT-qPCR SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 pandemic SARS-CoV-2 RNA SARS-CoV-2 seroprevalence serological seropositive individuals Seropositivity serum samples shown Social worker Sociodemographic swab sample tested the SARS-CoV-2 while [DOI] 10.1371/journal.pntd.0009754 PMC 바로가기 [Article Type] Research Article
Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study항 -SARS-COV-2 IgG 항체의 혈청 유병률, 스위스 제네바의 감염 위험 요인 및 관련 증상 : 인구 기반 연구Original Articles Published on 2021-10-192022-09-01 Journal: Scandinavian Journal of Public Health [Category] COVID19(2023년), Fulltext, MERS, SARS, 진단, [키워드] adjusted aims Anosmia anosmia/dysgeusia anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibodies association Bayesian Biology blood sample Blood samples children COVID-19 credible interval dysgeusia epidemic wave Factor female First wave highest IgG Immunoglobulin Immunoglobulin G individual individuals Infection less level of education lowest men participant Participants Population-based survey Questionnaires reduced remained risk risk factor Risk factors SARS-CoV-2 SARS-CoV-2 seroprevalence seropositive Seropositivity Seroprevalence significantly smoker Smokers Socioeconomic Factors socioeconomic risk factors Switzerland Symptom tested [DOI] 10.1177/14034948211048050 PMC 바로가기 [Article Type] Original Articles
Seroprevalence of SARS-CoV-2 in Croatian solid-organ transplant recipients크로아티아 고체 유기 이식 수용자에서 SARS-COV-2의 혈청 유병률Short Communication Published on 2021-10-152022-09-10 Journal: Biochemia Medica [Category] 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition anti-SARS-CoV-2 antibody Antibody titer Antibody titers asymptomatic patient asymptomatic patients collected Community coronavirus coronavirus disease COVID-19 COVID-19 immunity COVID-19 pandemic Croatia cross-sectional determine dynamic ELISA enzyme-linked immunosorbent enzyme-linked immunosorbent assay event IgG IgG antibodies Immunocompromised interquartile range IQR kidney transplant recipient kidney transplant recipients liver LTR LTRs material median neutralization test Participation Patient Population positive positive patient positive sample protective immunity questionnaire recipient reported respiratory Result risk SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 IgG SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody Seropositivity Seroprevalence serum sample serum samples severe acute respiratory syndrome Coronavirus significantly higher solid-organ transplant solid-organ transplant recipients Spain statistically significant Symptom symptomatic tested virus neutralization test VNT was performed [DOI] 10.11613/BM.2021.030901 PMC 바로가기 [Article Type] Short Communication
SARS-CoV-2 antibodies in Ontario health care workers during and after the first wave of the pandemic: a cohort study전염병의 첫 번째 물결 동안과 이후에 온타리오 의료 종사자의 SARS-CoV-2 항체: 코호트 연구Multicenter Study Published on 2021-10-122022-09-11 Journal: CMAJ open [Category] MERS, SARS, 진단, 치료기술, [키워드] 95% confidence interval adjusted adjusted odds ratio age antibody blood sample Blood samples Canada Care Chain Reaction Clustering cohort study Community community hospital conducted COVID-19 COVID-19 outbreak Critical detect enrolled enrolment evaluated exposure to female First wave Health Health care Health care worker health care workers highlighting hospital household IgG IgG antibodies IgG antibody Immunoglobulin Immunoglobulin G increased risk Infection median age multicentre multivariable logistic regression pandemic participant patient with COVID-19 patients with COVID-19 pediatric polymerase chain polymerase chain reaction Polymerase chain reaction testing Providing public health public health measure public health measures questionnaire risk factor SARS-CoV-2 SARS-CoV-2 antibody seropositive Seropositivity Seroprevalence symptomatic contact symptomatic contacts the median the strongest unit were excluded [DOI] 10.9778/cmajo.20210044 PMC 바로가기 [Article Type] Multicenter Study
Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of BrazilCommunication Published on 2021-10-122022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% CI age anti-SARS-CoV-2 antibody antibody reactivity assessment Brazil CoronaVac COVID-19 cross-sectional distribution dose Effectiveness evaluated Frequency greater group humoral immune response immune system in both groups individual Neutralizing Neutralizing antibodies neutralizing antibody Older Prevalence Receptor binding Region S1 and S2 SARS-CoV-2 Seropositivity significantly tested total antibody two groups Vaccine Volunteer [DOI] 10.3390/vaccines9101169 PMC 바로가기 [Article Type] Communication
Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)BNT162b2 mRNA SARS-CoV-2 백신의 추가 용량을 2회 백신 용량 후 적절한 체액 반응 없이 신장 이식 수용자에게 투여할 때 면역 억제 감소: 무작위 대조 시험 프로토콜(BECAME 연구)Article Published on 2021-10-112022-09-11 Journal: BMJ Open [Category] SARS, 임상, [키워드] All participant All participants Antibody Response antimetabolite approved BNT162b2 BNT162b2 mRNA BNT162b2 vaccine booster dose calculated consequence control group COVID-19 described dose eligible Endpoint Ethics humoral immunology Immunosuppression immunosuppressive Inadequate intervention group investigator-initiated kidney transplant recipient kidney transplant recipients Local local Ethics Committee mRNA observational study Open-label participant Patient patients Primary outcome prospective observational study protocol Rabin Medical Center randomised controlled randomised controlled trial receive recipients reduction regimen registration number renal Renal transplantation required Result Sample size SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Seropositivity solid organ solid organ transplant submitted T-cell Response tested Trial Vaccination strategy Vaccine vaccine dose written Informed Consent [DOI] 10.1136/bmjopen-2021-055611 PMC 바로가기 [Article Type] Article
Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans사람에서 SARS-CoV-2 감염 후 1년 동안 중화 항체의 지속성Research Article|Clinical Published on 2021-10-082022-09-10 Journal: European Journal of Immunology [Category] MERS, SARS, 변종, 진단, 치료법, [키워드] Alpha antibody Antibody titers B.1.1.7 B.1.351 B.1.617.2 Beta Concentration declined Delta develop Diagnosis disease expected Human humans IgG IgG antibodies Immunity individuals Infection less Mild Mild disease MOST NAb titer NAb titers Neutralizing antibodies neutralizing antibody Neutralizing antibody titer neutralizing antibody titers participant persistence proportion reduced SARS‐CoV‐2 SARS‐CoV‐2 infection SARS‐CoV‐2 spike SARS‐CoV‐2 seropositive Seropositivity Seroprevalence serum antibodies serum antibody Severe infection spike IgG subject subset variant variants variants of concern VOCs were assessed WT virus [DOI] 10.1002/eji.202149535 PMC 바로가기 [Article Type] Research Article|Clinical